Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Fudan University

Status and phase: Enrolling; Phase 3

Conditions: HR+/HER2- Breast Cancer; Advanced Breast Cancer

Treatments: Drug: Aromatase inhibitor and Fulvestrant; Drug: CDK4/6 Inhibitor; Drug: Apatinib

Study type: Interventional

Funder types: Other

Identifiers

NCT06447623

SCHBCC-N068

Details and patient eligibility

About

This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer. The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy.

Enrollment: 184 estimated patients

Sex: Female

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inclusion Criteria:

• Patients need to meet all of the following conditions

  • Patients must be ≥18 and ≤ 75 years of age;

  • Pathologically confirmed breast cancer is HR+/HER2- breast cancer (IHC ER >10%, or/and PR>10%, HER 0 OR +, if HER2++, FISH negative);

  • SNF4 subtype definition: SNF4 subtype confirmed by digital pathology of H&E sections;

  • Locally advanced breast cancer (radical local therapy is not possible) or metastatic breast cancer (without using adjuvant CDK4/6 inhibitors in the past, or one year after adjuvant CDK4/6 inhibitor therapy has ended);

  • No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer;

  • Patients with at least one measurable lesion that has not previously received radiation therapy and can be evaluated repeatedly according to RECIST 1.1;

  • The functions of the main organs are basically normal, and the following conditions are met:

    1. Blood routine examination standards should meet: HB≥90g/L (no blood transfusion within 14 days); ANC≥1.5×109/L; PLT≥75×109/L;
    2. Biochemical examination shall meet the following standards: TBIL≤1.5×ULN (upper limit of normal value); ALT and AST≤3 x ULN; In case of liver metastasis, ALT and AST≤5×ULN; Serum Cr ≤1.5×ULN, endogenous creatinine clearance > 50ml/min (Cockcroft-Gault formula);

  • ECOG performance status 0 or 1; The expected survival is more than 3 months;

  • Fertile female is required to use a medically approved contraceptive during study treatment and for at least 3 months after the last use of the study drug;

  • Patients voluntarily join the study, sign the informed consent, have good compliance, and cooperate with follow-up.

Exclusion criteria

• Patients with any of the following conditions were excluded from the study

  • Patients with central nervous system metastasis out of control (symptoms need to use glucocorticoids or mannitol).
  • A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;
  • Radiotherapy, chemotherapy, surgery, other targeted therapy, and immunotherapy for advanced HR+/HER2- breast cancer within 4 weeks before the first administration of drugs used in this study.
  • Pregnant or lactating patients;
  • Other malignancies within the previous 3 years, excluding cured skin basal cell carcinoma and cervical carcinoma in situ;
  • Significant comorbid medical conditions, including mental illnesses that the investigator or sponsor believes would adversely affect the patient's participation in the study;
  • Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies;
  • The investigator does not consider the patient suitable for participation in any other circumstances of the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

184 participants in 2 patient groups

Arm-A

Experimental group

Description:

Apatinib combined with cdk4/6i and Endocrine therapy.

Treatment:

Drug: Apatinib

Drug: CDK4/6 Inhibitor

Drug: Aromatase inhibitor and Fulvestrant

Arm-B

Active Comparator group

Description:

cdk4/6i and Endocrine therapy.

Treatment:

Drug: CDK4/6 Inhibitor

Drug: Aromatase inhibitor and Fulvestrant